Company news

Harrow, Inc. news in 2026

Harrow, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Harrow to Participate in Two Investor Conferences in November

November 12, 2026

Q3-2026 Letter to Stockholders

November 9, 2026

Harrow Announces Third Quarter 2026 Financial Results

November 9, 2026

Harrow Launches HarrowRx Platform

November 2, 2026

Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026

October 26, 2026

Harrow Closes Acquisition of TYRVAYA®

October 5, 2026

Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO

September 30, 2026

Harrow to Participate in Three Investor Conferences in September

September 1, 2026

Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections

August 20, 2026

Harrow Announces Second Quarter 2026 Financial Results

August 10, 2026

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

August 6, 2026

Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026

July 27, 2026

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

July 20, 2026

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

July 1, 2026

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

June 10, 2026

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

May 26, 2026

Harrow Announces First Quarter 2026 Financial Results

May 11, 2026

Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026

April 27, 2026

Harrow Announces the Issuance of J-Code for IOPIDINE® 1%

April 15, 2026

Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030

March 23, 2026

Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth

March 23, 2026

Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

March 17, 2026

Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference

March 3, 2026

Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication

March 2, 2026

Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance

March 2, 2026

Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026

February 18, 2026

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits

February 17, 2026

OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California

February 3, 2026

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

February 1, 2026

Calls in 2026

Decks in 2026